Bone marrow-derived mononuclear cell therapy alleviates left ventricular remodeling and improves heart function in rat-dilated cardiomyopathy

Critical Care Medicine

Volumn 37, Issue 4, 2009, Pages 1197-1205

  Sun, Cheuk Kwan ^a   Chang, Li Teh ^b   Sheu, Jiunn Jye ^a   Chiang, Chiang Hua ^c   Lee, Fan Yen ^a   Wu, Chiung Jen ^a   Chua, Sarah ^a   Fu, Morgan ^a   Yip, Hon Kan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

^c NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Bone marrow?derived mononuclear cell therapy; Dilated cardiomyopathy

Indexed keywords

CONNEXIN 43; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GELATINASE B; INTERLEUKIN 10; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN KINASE C EPSILON;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CELL DEATH; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HEART WEIGHT; MALE; MONONUCLEAR CELL; MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHY, DILATED; MALE; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR REMODELING;

EID: 67650477577     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819c0667     Document Type: Article

References (47)

1. Report WHOISFCTFDCC: Report, of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93:841-842
2. Dec GW, Fuster V: Idiopathic dilated cardiomyopathy. N Engl J Med 1995; 332: 1384-1386
3. ManolioTA, Baughman KL, Rodeheffer R, et al: Prevalence and etiology of dilated cardiomyopathy. Am J Cardiol 1992; 69:1458-1466
4. Deg GW, Fuster V: Idiopathic dilated cardio-myopathy. N Engl J Med 1994; 331: 1564-1575
5. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE inhibitor trials. JAMA 1995; 273: 1450-1456
6. Blum A, Miller H: Role of cytokines in heart failure. Am Heart J 1998; 135:81-86
7. Codd MB, Sugrue DD, Gersh BJ, et al: Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989; 80:564-572
8. Rakar S, Sinagra G, Di Lenarda A, et al: Epidemiology of dilated cardiomyopathy. A prospective post-mortem study of 5252 necropsies. Eur Heart J 1997; 18:117-123
9. Felker GM, Thompson RE, Hare JM, et al: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077-1084
10. Nikolaidis LA, Doverspike A, Huerbin R, et al: Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Circulation 2002; 105:2785-2790
11. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302
12. Pitt B, Poole-Wilson PA, Segal R: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587
13. Dandel M, Weng Y, Siniawski H, et al: Longterm results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. Circulation 2005; 112(Suppl):I37-I45
14. Taylor RGM, Carniel E, Mestroni L: Cardiomyopathy, familial dilated. Orphanet J Rare Dis 2006; 1:27
15. Tomita S, Ki RK, Weisel RD, et al: Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999; 100(Suppl II):II247-II256
16. Strauer BE, Brehm M, Zeus T, et al: Repair of infarcted myocardium by autologous intra-coronary mononuclear bone cell transplantation in humans. Circulation 2002; 106: 1913-1918
17. Tse HF, Kwong YL, Chan JK, et al: Angiogenesis in ischemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 4:47-49
18. Davani S, Marandin A, Merisin N, et al: Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation 2003; 108(Suppl II):II253-II258
19. Nagaya N, Kangawa K, Itoh T, et al: Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005; 112:1128-1135
20. Singal PK, Khaper N, Palace V, et al: The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 1998; 40:426-432
21. Ide T, Tsutsui H, Kinugawa S, et al: Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999; 85: 357-363
22. Ichihara S, Yamada Y, Ichihara G, et al: Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy. Biochem Biophys Res Commun 2006; 350:105-113
23. Tsutamoto T, Wada A, Matsumoto T, et al: Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardio-myopathy. J Am Coll Cardiol 2001; 37: 2086-2092
24. Garnier A, Fortin D, Delomenie C, et al: Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 2003; 551:491-501
25. Huss JM, Kelly DP: Mitochondrial energy metabolism in heart failure: A question of balance. J Clin Invest 2005; 115:547-555
26. Lerner DL, Yamada KA, Schuessler RB, et al: Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 2000; 101:547-552
27. Thum T, Bauersachs J, Poole-Wilson PA, et al: The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol 2005; 46:1799-1802
28. Kodama M, Zhang S, Hanawa H, et al: Effects of 15-deoxysperqualin on experimental autoimmune giant cell myocarditis of the rat. Circulation 1995; 91:1116-1122
29. Watanabe K, Ohta Y, Nakazawa M, et al: Low dose carvedilol inhibits progression of heart failure in rat with dilated cardiomyopathy. Br J Pharmacol 2000; 130:489-1495
30. Tomita S, Li RK, Weisel RD, et al: Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999; 100(Suppl III):II247-II256
31. Sheu JJ, Chang LT, Chiang CH, et al: Impact of diabetes on cardiomyocyte apoptosis and connexin43 gap junction integrity: Role of pharmacological modulation. Int Heart J 2007; 48:233-245
32. Libera LD, Ravara B, Gobbo V, et al: Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of carvedilol. J Mol Cell Cardiol 2005; 9:803-807
33. Mangi AA, Noiseux N, Kong D, et al: Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infracted hearts. Nat Med 2003; 9:1195-1201
34. Jackson KA, Majka SM, Wang H, et al: Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107:1395-1402
35. Quaini F, Urbanek K, Beltrami AP, et al: Chimerism of the transplanted heart. N Engl J Med 2002; 346:5-15
36. Makino S, Fukuda K, Miyoshi S, et al: Cardiomyocytes can be generated from marrow stromal cell in vitro. J Clin Invest 1999; 103: 697-705
37. Dai W, Hale SL, Martin BJ, et al: Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: Short- and long-term effects. Circulation 2005; 112: 214-223
38. Valgimigli M, Ceconi C, Malagutti P, et al: Tumor necrotic factor-á receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction. Circulation 2005; 111:863-870
39. Neumann FJ, Ott I, Gawaz M, et al: Cardiac release of cytokines and inflammatory response in acute myocardial infarction. Circulation 1995; 92:748-755
40. Suwa M, Nakano H, Kumagai S: Effects of chronic AICAR treatment on fiber composition, enzyme activity, ucp3, and pgc-1 in rat muscles. J Appl Physiol 2003; 95:960-968
41. Albert CJ, Ford DA: Protein kinase C translocation and PKC-dependent protein phosphorylation during myocardial ischemia. Am J Physiol 1999; 276:H642-H650
42. Vondriska TM, Klein JB, Ping P: Use of functional proteomics to investigate PKC-ε-mediated cardioprotection: The signaling module hypothesis. Am J physiol 2001; 280: H1434-H1441
43. Inagaki K, Hahn HS, Dorn GW II, et al: Additive protection of the ischemic heart ex vivo by combined treatment with ä-protein kinase C inhibitor and å-protein kinase C activator. Circulation 2003; 108:869-875
44. Baines CP, Zhang J, Wang GW, et al: Mitochondrial PKCå and KAPK form signaling modulates in the murine heart: Enhanced mitochondrial PKCå-MAPK interactions and differential MAPK activation in PKCå-induced cardioprotection. Circ Res 2002; 90: 390-397
45. Severs NJ, Rothery S, Dupont E, et al: Immunocytochemical analysis of connexin expression in healthy and diseased cardiovascular system. Microsc Res Tech 2001; 52: 301-322
46. Kirchhoff S, Nelles E, Hagendorff A, et al: Reduced cardiac conduction velocity and predisposition to arrhythmias in con-nexin40-deficient mice. Curr Biol 1998; 8:299-302
47. Peters NS, Green CR, Poole-Wilson PA, et al: Cardiac arrhythmogenesis and the gap junction. J Mol Cell Cardiol 1995; 27:37-44